CN110314192A - Attention deficit hyperactivity disorder therapeutic agent and preparation method thereof - Google Patents
Attention deficit hyperactivity disorder therapeutic agent and preparation method thereof Download PDFInfo
- Publication number
- CN110314192A CN110314192A CN201810269823.2A CN201810269823A CN110314192A CN 110314192 A CN110314192 A CN 110314192A CN 201810269823 A CN201810269823 A CN 201810269823A CN 110314192 A CN110314192 A CN 110314192A
- Authority
- CN
- China
- Prior art keywords
- attention deficit
- hyperactivity disorder
- deficit hyperactivity
- therapeutic agent
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of attention deficit hyperactivity disorder therapeutic agents and preparation method thereof.The drug includes following component: radix pseudostellariae, Rehmannia glutinosa, fructus lycii, Schisandra chinensis, Radix Polygalae, rhizoma acori graminei and Poria cocos.The preparation method of attention deficit hyperactivity disorder therapeutic agent is the following steps are included: step 1, Schisandra chinensis extract to obtain the first extract fine powder with ethyl alcohol；Step 2, rhizoma acori graminei steam distillation, aqueous solution and the dregs of a decoction after obtaining volatile oil, distillation；Volatile oil is with cyclodextrin encapsulated, and crushed after being dried is at the second extract fine powder；Step 3, other components add water to cook, and obtain filtrate；Step 4, the filtrate that aqueous solution and step 3 after the distillation obtained to step 2 obtain handles to obtain third extract fine powder；Step 5, extract fine powder and additive are mixed and is pelletized, dry attention deficit hyperactivity disorder therapeutic agent.Above-mentioned attention deficit hyperactivity disorder therapeutic agent can obtain higher cure rate, up to 92.5% in application.
Description
Technical field
The invention belongs to children ADHD therapeutic agent technical fields, more particularly to attention deficit hyperactivity disorder medicine
Object and preparation method thereof.
Background technique
Attention deficit hyperactivity disorder (ADHD), common a kind of mental handicape childhood China is known as hyperactivity, is.Table
Now for age and developmental level be disproportionate absent minded and attention the time is of short duration, hyperactivity hyperkinesia and impulsion, be often accompanied by
Difficulty of learning, conduct disorder and maladjustment.
Drug can improve attention deficit, reduce activity level, improve school grade to a certain extent, improve suffer from a short time
The relationship of person and kinsfolk.First kind drug is central stimulant, mainly methylphenidate and its controlled release tablet, commodity fame and gain he
Woods.Low dosage helps to improve attention, and high dose can improve more dynamic, impulsion symptoms, reduce behavioral problem.Central stimulant
6 years old or more patient is only limitted to use.Because there is central excitation effect, should not use at night, drug side-effect has loss of appetite, loses
Dormancy, headache, irritated and irritability etc. still cannot determine whether to influence growth and development.Central stimulant may induce or making patients
Symptom is twitched, comorbidity tic disorder patient is it is not recommended that use.Second class drug is that selective norepinephrine reuptake inhibits
Agent represents drug atomoxetine, and atomoxetine curative effect is suitable with methylphenidate, and adverse reaction is few, and tolerance is good, has been cited as
The first-line treatment drug of ADHD.Feature: being administered once daily, and curative effect sustainable 24 hours；It takes for a long time, without additive；The medicine rises
The effect time is slower than central stimulant, could generally occur curative effect after starting medication 1~2 week, not be suitable for needing acute
The ADHD patient for the treatment of.
Summary of the invention
The object of the present invention is to provide a kind of attention deficit hyperactivity disorder therapeutic agents and attention deficit hyperactivity disorder to treat
The preparation method of drug.
A kind of attention deficit hyperactivity disorder therapeutic agent includes following component: radix pseudostellariae, Rehmannia glutinosa, fructus lycii, Schisandra chinensis,
Radix Polygalae, rhizoma acori graminei and Poria cocos.
The preferred attention deficit hyperactivity disorder therapeutic agent includes the component of following weight proportion: radix pseudostellariae 300~
400, Rehmannia glutinosa 300~400, fructus lycii 200~300, Schisandra chinensis 200~300, Radix Polygalae 200~300, rhizoma acori graminei 200~300,
Poria cocos 300~400.
A kind of attention deficit hyperactivity disorder therapeutic agent is made of following component: radix pseudostellariae, Rehmannia glutinosa, fructus lycii, the five tastes
Son, Radix Polygalae, rhizoma acori graminei and Poria cocos.
The preferred attention deficit hyperactivity disorder therapeutic agent is made of following component: 300~400 weight of radix pseudostellariae
Part, 300~400 parts by weight of Rehmannia glutinosa, 200~300 parts by weight of fructus lycii, 200~300 parts by weight of Schisandra chinensis, Radix Polygalae 200~
300 parts by weight, 200~300 parts by weight of rhizoma acori graminei, 300~400 parts by weight of Poria cocos.
The preferred attention deficit hyperactivity disorder therapeutic agent is made of following component: radix pseudostellariae 380, Rehmannia glutinosa 380,
Fructus lycii 228, Schisandra chinensis 228, Radix Polygalae 228, rhizoma acori graminei 228, Poria cocos 380.
The preparation method of attention deficit hyperactivity disorder therapeutic agent the following steps are included:
Step 1, Schisandra chinensis is extracted with ethyl alcohol, is concentrated after filtrate recycling ethanol, and the first extract is ground into after being dried under reduced pressure
Fine powder；
Preferably, the detailed process of step 1 are as follows: Schisandra chinensis is crushed, is the heating of 60% ethyl alcohol with the mass percent of 10 times of quality
Three times, 2 hours every time, filtering, merging filtrate recycled ethyl alcohol to refluxing extraction, and concentration is dried under reduced pressure, crush to extract
First extract fine powder.
Step 2, rhizoma acori graminei steam distillation, aqueous solution and the dregs of a decoction after obtaining volatile oil, distillation；Volatile oil is pasted with ring
Spermatophore closes, and crushed after being dried is at the second extract fine powder；
Preferably, the detailed process of step 2 are as follows: rhizoma acori graminei extracts volatile oil with steam distillation, volatile oil with cyclodextrin encapsulated,
It is dried, crushed into fine powder；The another device preservation of aqueous solution after distillation, the dregs of a decoction add 8 times of amount water to decoct 1 hour time, filtration, filtrate and steaming
Aqueous solution after evaporating merges, the solution for standby after merging.
Step 3, radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add water to cook, and obtain filtrate；
Preferably, the detailed process of step 3 are as follows: radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add 12 times of quality water decoct 3 times, it is every
Secondary 1.5 hours, filtering, merging filtrate.
Step 4, the filtrate decompression that aqueous solution and step 3 after the distillation obtained to step 2 obtain is concentrated, and ethyl alcohol is added and stirs
Standing is mixed, supernatant is taken, recycling ethyl alcohol and being concentrated under reduced pressure is thick paste, and thick paste is dried under reduced pressure and is ground into third extract fine powder；
Preferably, the detailed process of step 4 are as follows: the solution after merging obtained by step 2 merges with step 3 gained filtrate, depressurizes dense
Relative density is the clear cream of 1.00~1.30g/ml under the conditions of being reduced to 60 DEG C, adds ethyl alcohol to make alcohol content 60wt%, stirs evenly, and is stood；
Supernatant is taken, the thick paste that relative density is 1.10~1.40g/ml under the conditions of recycling ethyl alcohol and being concentrated under reduced pressure into 60 DEG C, thick paste subtracts
It press dry dry and is ground into third extract fine powder.
Step 5, the first extract fine powder, the second extract fine powder, third extract fine powder and additive are mixed and are pelletized,
Dry attention deficit hyperactivity disorder therapeutic agent.
Attention deficit hyperactivity disorder patient can be treated using above-mentioned attention deficit hyperactivity disorder therapeutic agent, in application
Higher cure rate, up to 92.5% can be obtained.
Specific embodiment
The embodiment recorded herein is specific specific embodiment of the invention, for illustrating design of the invention,
Be it is explanatory and illustrative, should not be construed as the limitation to embodiment of the present invention and the scope of the invention.Except what is recorded herein
Outside embodiment, those skilled in the art can also based on the claim of this application book and specification disclosure of that using aobvious and
The other technical solutions being clear to, these technical solutions include using any obvious to making for the embodiment recorded herein
The technical solution of substitutions and modifications.
A kind of attention deficit hyperactivity disorder therapeutic agent includes following component: radix pseudostellariae, Rehmannia glutinosa, fructus lycii, the five tastes
Son, Radix Polygalae, rhizoma acori graminei and Poria cocos.
Preferably, attention deficit hyperactivity disorder therapeutic agent includes the component of following weight proportion: radix pseudostellariae 300~400,
Rehmannia glutinosa 300~400, fructus lycii 200~300, Schisandra chinensis 200~300, Radix Polygalae 200~300, rhizoma acori graminei 200~300, Poria cocos
300~400.
A kind of attention deficit hyperactivity disorder therapeutic agent, is made of following component: radix pseudostellariae, Rehmannia glutinosa, fructus lycii, the five tastes
Son, Radix Polygalae, rhizoma acori graminei and Poria cocos.
Preferably, attention deficit hyperactivity disorder therapeutic agent is made of following component: 300~400 parts by weight of radix pseudostellariae, ripe
300~400 parts by weight of glutinous rehmannia, 200~300 parts by weight of fructus lycii, 200~300 parts by weight of Schisandra chinensis, 200~300 weight of Radix Polygalae
Part, 200~300 parts by weight of rhizoma acori graminei, 300~400 parts by weight of Poria cocos.
The preparation method of attention deficit hyperactivity disorder therapeutic agent the following steps are included:
Step 1, Schisandra chinensis is extracted with ethyl alcohol, is concentrated after filtrate recycling ethanol, and the first extract is ground into after being dried under reduced pressure
Fine powder；
Step 2, rhizoma acori graminei steam distillation, aqueous solution and the dregs of a decoction after obtaining volatile oil, distillation；Volatile oil cyclodextrin packet
It closes, crushed after being dried is at the second extract fine powder；
Step 3, radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add water to cook, and obtain filtrate；
Step 4, the filtrate decompression that aqueous solution and step 3 after the distillation obtained to step 2 obtain is concentrated, and it is quiet that ethyl alcohol stirring is added
It sets, takes supernatant, recycling ethyl alcohol and being concentrated under reduced pressure is thick paste, and thick paste is dried under reduced pressure and is ground into third extract fine powder；
Step 5, the first extract fine powder, the second extract fine powder, third extract fine powder and additive are mixed and are pelletized, dry
Obtain attention deficit hyperactivity disorder therapeutic agent.
Embodiment 1
The attention deficit hyperactivity disorder therapeutic agent of the present embodiment is made of following component: 300 parts by weight of radix pseudostellariae, Rehmannia glutinosa
400 parts by weight, 200 parts by weight of fructus lycii, 300 parts by weight of Schisandra chinensis, 200 parts by weight of Radix Polygalae, 300 parts by weight of rhizoma acori graminei, Poria cocos
300 parts by weight.
Embodiment 2
The attention deficit hyperactivity disorder therapeutic agent of the present embodiment is made of following component: 400 parts by weight of radix pseudostellariae, Rehmannia glutinosa
300 parts by weight, 300 parts by weight of fructus lycii, 200 parts by weight of Schisandra chinensis, 300 parts by weight of Radix Polygalae, 200 parts by weight of rhizoma acori graminei, Poria cocos
400 parts by weight.
Embodiment 3
The attention deficit hyperactivity disorder therapeutic agent of the present embodiment is made of following component: radix pseudostellariae 380, Rehmannia glutinosa 380, fructus lycii
Son 228, Schisandra chinensis 228, Radix Polygalae 228, rhizoma acori graminei 228, Poria cocos 380.
Embodiment 4
The attention deficit hyperactivity disorder therapeutic agent of the present embodiment is made of following component: radix pseudostellariae 380, Rehmannia glutinosa 380, fructus lycii
Son 228, Schisandra chinensis 228, Radix Polygalae 228, rhizoma acori graminei 228, Poria cocos 380, Prunella vulgaris 300.
Embodiment 5
The attention deficit hyperactivity disorder therapeutic agent of the present embodiment is made of following component: radix pseudostellariae 380, Rehmannia glutinosa 380, fructus lycii
Son 228, Schisandra chinensis 228, Radix Polygalae 228, rhizoma acori graminei 228, Poria cocos 380, endothelium corneum gigeriae galli 160.
Embodiment 6
The preparation method of attention deficit hyperactivity disorder therapeutic agent the following steps are included:
Step 1, Schisandra chinensis is extracted with ethyl alcohol, is concentrated after filtrate recycling ethanol, and the first extract is ground into after being dried under reduced pressure
Fine powder；The detailed process of step 1 are as follows: Schisandra chinensis is crushed, is heated to reflux and is mentioned for 60% ethyl alcohol with the mass percent of 10 times of quality
It takes three times, 2 hours every time, filters, merging filtrate recycles ethyl alcohol, and concentration is dried under reduced pressure, and crush first mentioning to extract
Take object fine powder.
Step 2, rhizoma acori graminei steam distillation, aqueous solution and the dregs of a decoction after obtaining volatile oil, distillation；Volatile oil is pasted with ring
Spermatophore closes, and crushed after being dried is at the second extract fine powder；The detailed process of step 2 are as follows: the extraction of rhizoma acori graminei steam distillation is waved
Hair oil, volatile oil are dried, crushed into fine powder with cyclodextrin encapsulated；The another device of aqueous solution after distillation saves, and the dregs of a decoction add 8 times of amount water
It decocts 1 hour time, filtration, filtrate merges with the aqueous solution after distillation, the solution for standby after merging.
Step 3, radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add water to cook, and obtain filtrate；The detailed process of step 3 are as follows: too
Sub- ginseng, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add 12 times of quality water to decoct 3 times, 1.5 hours every time, filtering, merging filtrate.
Step 4, the filtrate decompression that aqueous solution and step 3 after the distillation obtained to step 2 obtain is concentrated, and ethyl alcohol is added and stirs
Standing is mixed, supernatant is taken, recycling ethyl alcohol and being concentrated under reduced pressure is thick paste, and thick paste is dried under reduced pressure and is ground into third extract fine powder；
The detailed process of step 4 are as follows: the solution after merging obtained by step 2 merges with step 3 gained filtrate, is concentrated under reduced pressure into 60 DEG C of conditions
Lower relative density is the clear cream of 1.00~1.30g/ml, adds ethyl alcohol to make alcohol content 60wt%, stirs evenly, and is stood；Supernatant is taken, is returned
The thick paste that relative density is 1.10~1.40g/ml under the conditions of receiving ethyl alcohol and being concentrated under reduced pressure into 60 DEG C, thick paste are dried under reduced pressure and crush
At third extract fine powder.
Step 5, the first extract fine powder, the second extract fine powder, third extract fine powder and dextrin are mixed and are pelletized, and are done
It is dry to obtain attention deficit hyperactivity disorder therapeutic agent.
In 4 medicine preparation of embodiment, Prunella vulgaris adds water to cook in step 3；In 5 medicine preparation of embodiment, in chicken
Gold adds water to cook in step 3.
Embodiment 1-6 formula is prepared according to the method described above to be respectively obtained drug 1A (formula of corresponding embodiment 1), 2A, 3A,
4A, 5A.Save backup carry out effect measuring.
Embodiment 7
Radix pseudostellariae, Rehmannia glutinosa, fructus lycii, Schisandra chinensis, Radix Polygalae, rhizoma acori graminei, all medicine components such as Poria cocos add 12 times of quality decoctings
It boils 3 times, every time 1.5 hours, filters, merging filtrate.In 4 medicine preparation of embodiment, Prunella vulgaris and other compositions add water together
It decocts；In 5 medicine preparation of embodiment, endothelium corneum gigeriae galli adds water to cook together with other compositions.
Filtrate decompression concentration is added ethyl alcohol stirring and stands, takes supernatant, and recycling ethyl alcohol and being concentrated under reduced pressure is thick paste, thick paste
It is dried under reduced pressure and is ground into third extract fine powder；Detailed process are as follows: filtrate merging is relatively close under the conditions of being concentrated under reduced pressure into 60 DEG C
Degree is the clear cream of 1.00~1.30g/ml, adds ethyl alcohol to make alcohol content 60wt%, stirs evenly, and is stood；Supernatant is taken, recycling ethyl alcohol is simultaneously
Relative density is the thick paste of 1.10~1.40g/ml under the conditions of being concentrated under reduced pressure into 60 DEG C, and thick paste is dried under reduced pressure and is ground into extract
Fine powder.Extract fine powder and dextrin are mixed and are pelletized, dry attention deficit hyperactivity disorder therapeutic agent.In 4 drug of embodiment
When preparation, Prunella vulgaris adds water to cook together with other compositions；In 5 medicine preparation of embodiment, endothelium corneum gigeriae galli and other compositions are together
It adds water to cook.
Embodiment 1-6 formula is prepared according to the method described above respectively obtains drug 1B, 2B, 3B, 4B, 5B.Save backup progress
Effect measuring.
Embodiment 8
Conditioning of the present invention by Chinese medicine, YIN and YANG balance regulating, tranquilizing and allaying excitement, while warming spleen and appetizing, tonifying middle-Jiao and Qi, blood-nourishing calming heart, medicine
Taste is easy to receive, convenient for taking to pediatric patient.
Curative effect judgement:
Effective: clinical symptoms all disappear, no recurrence.
Effective: clinical symptoms disappear substantially, and activity significantly reduces, can complete independently operation as required, it is relatively conscientious to do things, multiple
Hair rate is less than 30%.
Invalid: clinical symptoms are not improved, activity it is more, cannot complete independently operation as required, act in a perfunctory manner, have
Begin endless, recurrence rate is greater than 70%.
Treatment results: 900 ADHD children patients, each experimental group about 80 are treated using said medicine
Name patient.It is three times per day warmly taken after meal using 1 course for the treatment of Chinese medicine of the invention, 12 grams every time, 2 weeks as a treatment course.Specifically
Data are shown in Table 1.
It positive can utilize the drug of the method for the present invention preparation can at application by said medicine Contrast on effect data
Obtain higher cure rate, up to 92.5%.Furthermore inventor has found some patientss in the experimentation for carrying out effect of drugs
There is side effect generation, is embodied in patient and has a stomach upset after the tablet has been ingested, dry, drug of inventor's discovery in addition endothelium corneum gigeriae galli
In, generation without side-effects after patient's medication, it is preferred that the additive amount of endothelium corneum gigeriae galli is 100 to 300 parts by weight.
Each technical characteristic of above-mentioned disclosure is not limited to disclosed and other feature combination, and those skilled in the art are also
Can carry out other combinations between each technical characteristic according to the purpose of invention, be subject to realize the present invention purpose.
Claims (10)
1. a kind of attention deficit hyperactivity disorder therapeutic agent, which is characterized in that include following component: radix pseudostellariae, Rehmannia glutinosa, fructus lycii
Son, Schisandra chinensis, Radix Polygalae, rhizoma acori graminei and Poria cocos.
2. attention deficit hyperactivity disorder therapeutic agent according to claim 1, which is characterized in that include following weight proportion
Component: radix pseudostellariae 300~400, Rehmannia glutinosa 300~400, fructus lycii 200~300, Schisandra chinensis 200~300, Radix Polygalae 200~
300, rhizoma acori graminei 200~300, Poria cocos 300~400.
3. a kind of attention deficit hyperactivity disorder therapeutic agent, which is characterized in that be made of following component: radix pseudostellariae, Rehmannia glutinosa, Chinese holly
Matrimony vine, Schisandra chinensis, Radix Polygalae, rhizoma acori graminei and Poria cocos.
4. attention deficit hyperactivity disorder therapeutic agent according to claim 3, which is characterized in that be made of following component:
300~400 parts by weight of radix pseudostellariae, 300~400 parts by weight of Rehmannia glutinosa, 200~300 parts by weight of fructus lycii, Schisandra chinensis 200~300
Parts by weight, 200~300 parts by weight of Radix Polygalae, 200~300 parts by weight of rhizoma acori graminei, 300~400 parts by weight of Poria cocos.
5. attention deficit hyperactivity disorder therapeutic agent according to claim 3, which is characterized in that by following weight proportion
Component is constituted: radix pseudostellariae 380, Rehmannia glutinosa 380, fructus lycii 228, Schisandra chinensis 228, Radix Polygalae 228, rhizoma acori graminei 228, Poria cocos 380.
6. the preparation method of any one of the claim 1-5 attention deficit hyperactivity disorder therapeutic agent, which is characterized in that including
Following steps:
Step 1, Schisandra chinensis is extracted with ethyl alcohol, is concentrated after filtrate recycling ethanol, and the first extract is ground into after being dried under reduced pressure
Fine powder；
Step 2, rhizoma acori graminei steam distillation, aqueous solution and the dregs of a decoction after obtaining volatile oil, distillation；Volatile oil cyclodextrin packet
It closes, crushed after being dried is at the second extract fine powder；
Step 3, radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add water to cook, and obtain filtrate；
Step 4, the filtrate decompression that aqueous solution and step 3 after the distillation obtained to step 2 obtain is concentrated, and it is quiet that ethyl alcohol stirring is added
It sets, takes supernatant, recycling ethyl alcohol and being concentrated under reduced pressure is thick paste, and thick paste is dried under reduced pressure and is ground into third extract fine powder；
Step 5, the first extract fine powder, the second extract fine powder, third extract fine powder and additive are mixed and are pelletized, dry
Obtain attention deficit hyperactivity disorder therapeutic agent.
7. the preparation method of attention deficit hyperactivity disorder therapeutic agent according to claim 6, which is characterized in that step 1
Detailed process are as follows: Schisandra chinensis is crushed, with the mass percents of 10 times of quality be 60% ethyl alcohol heating and refluxing extraction three times, often
Secondary 2 hours, filtering, merging filtrate recycled ethyl alcohol, and concentration is dried under reduced pressure, carries out crushing to obtain the first extract fine powder to extract.
8. the preparation method of attention deficit hyperactivity disorder therapeutic agent according to claim 6, which is characterized in that step 2
Detailed process are as follows: rhizoma acori graminei extracts volatile oil with steam distillation, and volatile oil is dried, crushed into fine powder with cyclodextrin encapsulated；
The another device of aqueous solution after distillation saves, and the dregs of a decoction add 8 times of amount water to decoct 1 hour time, filtration, and the aqueous solution after filtrate and distillation closes
And the solution for standby after merging.
9. the preparation method of attention deficit hyperactivity disorder therapeutic agent according to claim 8, which is characterized in that step 3
Detailed process are as follows: radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Poria cocos, Radix Polygalae add 12 times of quality water to decoct 3 times, 1.5 hours every time, filtering,
Merging filtrate.
10. the preparation method of attention deficit hyperactivity disorder therapeutic agent according to claim 9, which is characterized in that step 4
Detailed process are as follows: obtained by step 2 merge after solution merge with step 3 gained filtrate, phase under the conditions of being concentrated under reduced pressure into 60 DEG C
The clear cream for being 1.00~1.30g/ml to density, adds ethyl alcohol to make alcohol content 60wt%, stirs evenly, and stands；Supernatant is taken, second is recycled
Alcohol and relative density is the thick paste of 1.10~1.40g/ml under the conditions of being concentrated under reduced pressure into 60 DEG C, thick paste are dried under reduced pressure and are ground into the
Three extract fine powders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810269823.2A CN110314192A (en) | 2018-03-29 | 2018-03-29 | Attention deficit hyperactivity disorder therapeutic agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810269823.2A CN110314192A (en) | 2018-03-29 | 2018-03-29 | Attention deficit hyperactivity disorder therapeutic agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110314192A true CN110314192A (en) | 2019-10-11 |
Family
ID=68110698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810269823.2A Pending CN110314192A (en) | 2018-03-29 | 2018-03-29 | Attention deficit hyperactivity disorder therapeutic agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110314192A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022132214A1 (en) * | 2020-12-14 | 2022-06-23 | Biolite, Inc. | Polygala extract for the treatment of attention-deficit hyperactivity disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107029070A (en) * | 2017-05-11 | 2017-08-11 | 北京三友联恒科技有限责任公司 | It is a kind of to treat the preparation method that obstacle Chinese medicine composition is moved child attention defect more |
-
2018
- 2018-03-29 CN CN201810269823.2A patent/CN110314192A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107029070A (en) * | 2017-05-11 | 2017-08-11 | 北京三友联恒科技有限责任公司 | It is a kind of to treat the preparation method that obstacle Chinese medicine composition is moved child attention defect more |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022132214A1 (en) * | 2020-12-14 | 2022-06-23 | Biolite, Inc. | Polygala extract for the treatment of attention-deficit hyperactivity disorder |
| US11857592B2 (en) | 2020-12-14 | 2024-01-02 | Biolite, Inc. | Polygala extract for the treatment of attention-deficit hyperactivity disorder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104887713A (en) | Preparing method of oyster active extract having functions of producing sperm to tonify the kidney and improving sexual function | |
| CN103932173A (en) | Composition for dispelling alcohol effect and protecting liver | |
| KR101953441B1 (en) | Composition for hangover annul material based on oriental medicine material, manufacturing method for pill type hangover annul material using the same, and pill type hangover annul material manufactured by the same | |
| CN103083505A (en) | Liver-soothing and qi-regulating traditional Chinese medicine composition used for treating depression, and preparation method thereof | |
| CN102626160B (en) | Brain-nourishing nutritional food, brain-nourishing tea granules | |
| CN104431064A (en) | Blood glucose-lowering tea and preparation method thereof | |
| CN110664906B (en) | Preparation method of health food with blood sugar reducing function | |
| CN104585418A (en) | Solid herbal tea with effect of assisting blood pressure reduction and preparation method of solid herbal tea | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN110314192A (en) | Attention deficit hyperactivity disorder therapeutic agent and preparation method thereof | |
| CN104337920B (en) | Traditional Chinese medicine composition for improving sleep quality | |
| CN102669345A (en) | Brain nourishing nutrition food of brain nourishing tea granule | |
| CN102846806A (en) | Vein circulation promoting and fat reducing granule and preparation method thereof | |
| CN103656164A (en) | Traditional Chinese medicine composition for nourishing yin, nourishing blood, tonifying heart and soothing nerves and preparation method thereof | |
| CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
| CN107616277B (en) | Respiratory tract health-care tea and preparation method and application thereof | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN104623280A (en) | Health product for reducing blood sugar and preparation method thereof | |
| CN104222400A (en) | Pu'er tea cream with functions of dispelling alcohol effect, protecting liver, nourishing heart and tranquilizing mind and processing method thereof | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN103751692B (en) | Special invigorating capsule of a kind of Testis et penis callorhini and preparation method thereof | |
| CN104000180A (en) | Ginseng compound assisting in blood sugar level regulation and preparing method and application thereof | |
| CN107320665A (en) | Treat precocious pharmaceutical composition of child and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191011 |
|
| WD01 | Invention patent application deemed withdrawn after publication |